866 related articles for article (PubMed ID: 30383140)
1. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
2. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
4. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Joensuu H
Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
[TBL] [Abstract][Full Text] [Related]
6. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Ramadori G; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Nilsson B; Sihto H; Bono P; Kallio R; Junnila J; Alvegård T; Reichardt P
J Clin Oncol; 2016 Jan; 34(3):244-50. PubMed ID: 26527782
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
[TBL] [Abstract][Full Text] [Related]
9. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG
JAMA Surg; 2020 Jun; 155(6):e200397. PubMed ID: 32236507
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
11. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
12. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
Guérin A; Sasane M; Keir CH; Gauthier G; Macalalad AR; Wu EQ; Conley AP
JAMA Oncol; 2015 Sep; 1(6):797-805. PubMed ID: 26204106
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
15. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
17. Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
Reichardt P; Schlemmer M; Delgado Perez JR; Papai Z; Prausova J; Melichar B; Fumagalli E; Barone C; Bauer S; Pustowka A; Crippa S; Castellana R; Quiering C; Le Cesne A
Oncol Res Treat; 2019; 42(12):629-635. PubMed ID: 31550719
[TBL] [Abstract][Full Text] [Related]
18. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
19. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2012; 17(7):992-7. PubMed ID: 22643537
[TBL] [Abstract][Full Text] [Related]
20. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
Cohen MH; Cortazar P; Justice R; Pazdur R
Oncologist; 2010; 15(3):300-7. PubMed ID: 20200041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]